Simon D. Campion net worth and biography

Simon Campion Biography and Net Worth

Simon D. Campion serves as executive vice president and president of the Interventional segment of BD (Becton, Dickinson and Company), a leading global medical technology company headquartered in Franklin Lakes, New Jersey. In this role, he is responsible for driving the global operational, commercial and financial performance of the three business units that comprise the segment, including BD Peripheral Intervention, BD Surgery and BD Urology & Critical Care. Campion is also a member of the BD Executive Leadership Team.

In 2017, when BD completed its acquisition of C. R. Bard, Inc., a leading medical technology company in the fields of vascular, urology and surgical specialty products, Campion was named worldwide president of the company’s newly created BD Surgery business unit. He was responsible for the integration of BD and Bard’s surgery-related offerings.

Campion joined Bard in 2008, initially serving as global marketing director for stents and stent grafts, and then he was named to marketing and general management roles of increased scope and responsibility within multiple Bard businesses, including as president of the company’s surgery business, Davol, after serving as its vice president and general manager.

Campion earned a bachelor’s degree in engineering and a doctorate in mechanical engineering from the University of Limerick, Ireland. He also earned a master’s degree in business administration from Open University in the United Kingdom.

What is Simon D. Campion's net worth?: The estimated net worth of Simon D. Campion is at least $2.56 million as of February 4th, 2020. Mr. Campion owns 11,296 shares of Becton, Dickinson and Company stock worth more than $2,557,719 as of March 15th. This net worth evaluation does not reflect any other assets that Mr. Campion may own. Learn More about Simon D. Campion's net worth.
How do I contact Simon D. Campion?: The corporate mailing address for Mr. Campion and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at investor.relations@bd.com. Learn More on Simon D. Campion's contact information.
Has Simon D. Campion been buying or selling shares of Becton, Dickinson and Company?: Simon D. Campion has not been actively trading shares of Becton, Dickinson and Company during the last ninety days. Most recently, Simon D. Campion sold 8,085 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $285.09, for a transaction totalling $2,304,952.65. Following the completion of the sale, the executive vice president now directly owns 11,296 shares of the company's stock, valued at $3,220,376.64. Learn More on Simon D. Campion's trading history.
Who are Becton, Dickinson and Company's active insiders?: Becton, Dickinson and Company's insider roster includes Richard Byrd (EVP and President, Interventional Segment ), Richard Byrd (EVP), Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), Jeffrey Henderson (Director), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Shana Neal (EVP and Chief People Officer), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), Bertram Scott (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.
Are insiders buying or selling shares of Becton, Dickinson and Company?: During the last year, Becton, Dickinson and Company insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $350,430.00. During the last year, insiders at the medical instruments supplier sold shares 12 times. They sold a total of 21,099 shares worth more than $4,840,015.53. The most recent insider tranaction occured on March, 12th when EVP Richard Byrd sold 1,940 shares worth more than $436,325.40. Insiders at Becton, Dickinson and Company own 0.4% of the company. Learn More about insider trades at Becton, Dickinson and Company.
Information on this page was last updated on 3/12/2025.

Simon D. Campion Insider Trading History at Becton, Dickinson and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/4/2020	Sell	8,085	$285.09	$2,304,952.65	11,296
6/12/2019	Sell	2,903	$236.94	$687,836.82	9,408

Simon D. Campion Buying and Selling Activity at Becton, Dickinson and Company

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Today's Range

Now: $226.43

$221.98

$226.47

50 Day Range

MA: $232.78

$222.65

$249.75

2 Week Range

Now: $226.43

$218.75

$251.99

Volume

1,157,171 shs

Average Volume

1,514,823 shs

Market Capitalization

$65.02 billion

P/E Ratio

37.61

Dividend Yield

1.81%

Beta

0.35